Innate Pharma to meet investors at Boral conference
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, reported that its executive team will hold one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026.
Rhea-AI Filing Summary
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, reported that its executive team will hold one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026. The company highlights a portfolio of next-generation antibody therapeutics, including IPH4502, lacutamab and monalizumab, developed alone or in collaboration with partners such as AstraZeneca and Sanofi. Headquartered in Marseille with a U.S. office in Rockville, Innate is listed on Euronext Paris and Nasdaq and directs readers to its French and U.S. regulatory filings for detailed risk factors.
Positive
- None.
Negative
- None.
Key Figures
Investor conference date: May 7, 2026
Press release time: 7:00 A.M. CEST
Latest annual period referenced: Year ended December 31, 2025
3 metrics
Investor conference date
May 7, 2026
D. Boral Capital Global Conference in New York
Press release time
7:00 A.M. CEST
Marseille, France announcement time
Latest annual period referenced
Year ended December 31, 2025
Form 20-F mentioned for risk factors
Key Terms
clinical-stage biotechnology, antibody therapeutics, Nectin-4 ADC, cutaneous T cell lymphomas, +2 more
6 terms
clinical-stage biotechnology financial
"Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients."
Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.
antibody therapeutics medical
"Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics."
Antibody therapeutics are medicines made from proteins the immune system uses, engineered to stick to specific molecules or cells to block disease or mark them for removal. They matter to investors because successful antibody drugs can command high prices and large markets, but their value hinges on clinical trial outcomes, manufacturing complexity, regulatory approval and patent protection—like custom-made keys that can open big rewards or be hard to replicate.
Nectin-4 ADC medical
"IPH4502, a differentiated Nectin-4 ADC developed in solid tumors,"
cutaneous T cell lymphomas medical
"lacunatamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas,"
Universal Registration Document regulatory
"refer to the Risk Factors section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
Annual Report on Form 20-F regulatory
"including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025,"
An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Innate Pharma (IPHA) announce in this Form 6-K?
Innate Pharma announced that its executive team will participate in one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026, highlighting ongoing investor engagement alongside its immuno-oncology development activities.
When and where is Innate Pharma (IPHA) meeting investors?
Innate Pharma executives will meet investors at the D. Boral Capital Global Conference on May 7, 2026, in New York, USA. This conference provides an opportunity for direct discussions with investors about the company’s pipeline of antibody-based cancer immunotherapies.
What type of company is Innate Pharma (IPHA)?
Innate Pharma is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. It focuses on antibody engineering and innovative target identification to create next-generation antibody therapeutics aimed at areas of high unmet medical need.
Which key drug candidates is Innate Pharma (IPHA) developing?
Innate Pharma is advancing IPH4502, a Nectin-4 antibody-drug conjugate in solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed with AstraZeneca in non-small cell lung cancer.
Where can investors find Innate Pharma (IPHA) risk factors and filings?
Investors can review Innate Pharma’s risk factors in its Universal Registration Document filed with the AMF and its Annual Report on Form 20-F for the year ended December 31, 2025, along with subsequent filings made public with the AMF and SEC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
